Could HIV drugs tame a rare immune disease in kids?
NCT ID NCT02363452
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This small pilot study tested whether drugs normally used for HIV could help children with Aicardi-Goutières syndrome (AGS), a rare genetic disorder that causes severe brain inflammation. The trial gave 11 children a combination of three reverse transcriptase inhibitors to see if it could lower their interferon levels, a key marker of inflammation. The goal was to check safety and whether the drugs could normalize the immune overreaction seen in AGS.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Reverse transcriptase inhibitors (zidovudine, lamivudine, abacavir)
- What this could lead to
- If it works, this could point toward a treatment that reduces harmful inflammation in children with Aicardi-Goutières syndrome.
- What could go wrong
- This is a very small, early-phase pilot study with only 11 participants. It is designed to check if the drug can lower certain immune markers, not yet to prove it helps symptoms or changes the course of the disease. Side effects from the drugs are possible.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AICARDI-GOUTIÈRES SYNDROME (AGS) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Hôpital Necker - Enfants Malades
Paris, 75015, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.